Skip to main content
    I

    Inhibikase Therapeutics Inc (IKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.45
    -0.07 (-4.61%)

    Market Cap: $213.21M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Inhibikase Therapeutics Inc (IKT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Inhibikase Therapeutics are Inovio Pharmaceuticals (INO), Bicycle Therapeutics (BCYC) and Bright Minds Biosciences (DRUG). By market cap, Inhibikase Therapeutics ranks 5th of the 13 companies on this page; Prelude Therapeutics (PRLD) is the largest at $275.32M.

    Peer Comparison

    IKT's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Inhibikase Therapeutics (IKT)$213.21MN/AN/A0.0%N/A-100.0%0.00%
    Inovio Pharmaceuticals Inc (INO)$267.85MN/A462.0x0.0%N/A-100.0%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Bright Minds Biosciences Inc (DRUG)$227.96MN/AN/A0.0%-11.2%0.0%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    InflaRx N.V. (IFRX)$172.42MN/AN/A0.0%N/A-80.8%0.00%
    Keros Therapeutics Inc (KROS)$202.13MN/A4.9x-151.4%N/A180.5%0.00%
    Sionna Therapeutics, Inc. Common Stock (SION)$150.63MN/AN/A0.0%N/A0.0%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Whitehawk Therapeutics, Inc. (WHWK)$180.57MN/AN/A0.0%N/A-100.0%0.00%
    Eledon Pharmaceuticals Inc (ELDN)$178.63MN/AN/A0.0%N/A0.0%0.00%
    Upstream Bio, Inc. (UPB)$152.38MN/A41.0x0.0%N/A-42.2%0.00%
    Pyxis Oncology Inc (PYXS)$188.98MN/A11.6x0.0%N/A0.0%0.00%
    Peer median$184.77MN/A11.6x0.0%-11.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Inhibikase Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Inovio Pharmaceuticals Inc (INO)
    Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development...
    INO competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Bright Minds Biosciences Inc (DRUG)
    Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies...
    DRUG competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    InflaRx N.V. (IFRX)
    InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States.
    IFRX competitors
    Keros Therapeutics Inc (KROS)
    Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery...
    KROS competitors
    Sionna Therapeutics, Inc. Common Stock (SION)
    Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders...
    SION competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Whitehawk Therapeutics, Inc. (WHWK)
    Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
    WHWK competitors
    Eledon Pharmaceuticals Inc (ELDN)
    Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases...
    ELDN competitors
    Upstream Bio, Inc. (UPB)
    Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
    UPB competitors
    Pyxis Oncology Inc (PYXS)
    Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)...
    PYXS competitors

    Frequently Asked Questions About IKT

    Who are Inhibikase Therapeutics' main competitors?

    The companies most similar to Inhibikase Therapeutics include Inovio Pharmaceuticals (INO), Bicycle Therapeutics (BCYC), Bright Minds Biosciences (DRUG), Invivyd (IVVD) and InflaRx (IFRX), listed from the closest match.

    Who is Inhibikase Therapeutics' biggest competitor?

    Prelude Therapeutics (PRLD) is the largest of the similar companies at $275.32M; Inovio Pharmaceuticals (INO) is the closest match by business profile, size, sector and industry.

    How does IKT stock compare with its competitors?

    IKT's net margin is 0.0% against a peer median of 0.0%.

    Which of Inhibikase Therapeutics' competitors pays a higher dividend?

    Inhibikase Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Inhibikase Therapeutics bigger than its competitors?

    No. Inhibikase Therapeutics is 5th by market cap among the 13 companies on this page; the largest is Prelude Therapeutics (PRLD) at $275.32M.